Table 3

Secondary and other efficacy endpoint responses at week 12

Embedded Image

  • *p≤0.05, **p≤0.01, ***p≤0.001 versus placebo.

  • ASAS40, ASAS5/6 and BASDAI50 used NRI/LOCF for missing values.

  • ASDAS clinical improvement=improvement ≥1.1 units.

  • ASDAS major response=improvement ≥2.0 units.

  • ASAS, Assessment of SpondyloArthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASspiMRI, Ankylosing Spondylitis spine MRI; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; Berlin score, Berlin modified ASspiMRI score; hsCRP, high-sensitivity C reactive protein; LOCF, last observation carried forward; LS, least squares; NRI, non-responder imputation; SI, sacroiliac; SPARCC, SPondyloArthritis Research Consortium of Canada.